David A Sallman MD

PubMed

• Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression.
  Luis E Aguirre, Somedeb Ball, Akriti Jain, Najla Al Ali, David A Sallman
  Clinical Lymphoma, Myeloma & Leukemia. 2025-03-29
• 1 citations
  Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
  Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang
  Blood. 2025-03-27
• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
  Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand
  Journal of the National Comprehensive Cancer Network. 2025-03-01

Abstracts/Posters

• A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti_Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocyti...
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
  David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. 
  2019 ASCO Annual Meeting - 6/1/2019
• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all